Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T5535 |
ERK5-IN-2
|
ERK | MAPK |
ERK5-IN-2 是具有口服活性,亚微摩尔效力,选择性ERK5抑制剂,对ERK5和ERK5 MEF2D 的IC50s 分别是 0.82 和 3 μM。它抑制肿瘤异种移植生长和碱性成纤维细胞生长因子驱动的基质胶塞血管生成。 | |||
T38377 |
ADTL-EI1712
ADTL-EI1712 |
||
ADTL-EI1712 is a dual inhibitor of ERK1 and ERK5 (IC50s = 40.43 and 64.5 nM, respectively).1It reduces ERK1 and ERK5 activity by 93.5% and 89.4%, respectively, but also inhibits ERK2 activity by 92.7%, in a panel of 100 kinases at 1 μM. ADTL-EI1712 inhibits proliferation of HL-60 and MKN74, but not HeLa, cancer cells (IC50s = 1.26, 2.55, and >50 μM, respectively). It reduces tumor growth and intratumor phosphorylation of ERK1/2 and ERK5 in an MKN74 mouse xenograft model when administered at a do... | |||
T35536 |
Tpl2 Kinase Inhibitor (hydrochloride)
|
||
Tpl2 kinase inhibitor is an inhibitor of tumor progression locus 2 (Tpl2; IC50= 0.05 μM).1It is selective for Tpl2 over MEK, p38 MAPK, Src, MK2, and PKC (IC50s = >40, 180, >400, 110, and >400 μM, respectively). Tpl2 kinase inhibitor inhibits LPS-induced TNF-α production in isolated human monocytes and whole blood (IC50s = 0.7 and 8.5 μM, respectively). It enhances differentiation induced by calcitriol in HL-60 and U937 leukemia cells when used at a concentration of 5 μM.2Tpl2 kinase inhibitor (5... |